The Impact of Reducing of Hepatitis B Virus (HBV) and Human Papillomavirus (HPV)-Related Cancers on Treatment Patterns in Germany, Italy, and Spain
Author(s)
Amanda L. Eiden, MBA, MPH, PhD1, Goran Bencina, PhD2, Josh Lankin, MSc3, Gaelle Farge, PhD4, Olga Ovcinnikova-Hutchings, MS5, Marcie Fisher-Borne, PhD, MPH, MSW6, Simona Fantoni, BS7, Vanessa Angelucci, MS7, Otavio Clark, PhD, MD8.
1Health Outcomes Research, Merck & Co., Inc., Philadelphia, PA, USA, 2MSD Spain, Barcelona, Spain, 3Oracle, New York, NY, USA, 4MSD France, Paris, France, 5MSD (UK) Ltd, London, United Kingdom, 6Merck & Co. Inc, Rahway, NJ, USA, 7MSD Italy, Rome, Italy, 8Oracle Life Science, New York, NY, USA.
1Health Outcomes Research, Merck & Co., Inc., Philadelphia, PA, USA, 2MSD Spain, Barcelona, Spain, 3Oracle, New York, NY, USA, 4MSD France, Paris, France, 5MSD (UK) Ltd, London, United Kingdom, 6Merck & Co. Inc, Rahway, NJ, USA, 7MSD Italy, Rome, Italy, 8Oracle Life Science, New York, NY, USA.
OBJECTIVES: To evaluate the impact of the World Health Organization (WHO) elimination strategies and additional scenarios for viral hepatitis, cervical cancer (CC), and other HPV-related cancers on cancer-related healthcare resource utilization (HCRU) in Germany, Italy, and Spain.
METHODS: We assessed the 2023 incidence and HCRU for cancer treatment for hepatocellular carcinoma (HCC) and each HPV-related cancer. We then evaluated potential effects of achieving WHO cancer elimination strategies for HCC and CC by modeling a 90% reduction in HBV infections and reducing CC incidence to fewer than 4 cases per 100,000 women. Next, we evaluated a hypothetical scenario to estimate a 90% reduction in other HPV-related cancers including head & neck, anal, penile, vulvar, and vaginal. The 2023 epidemiological data was sourced from the CancerMPact® database, and we applied Population Attributable Fractions (PAFs) to estimate cancer cases linked to HBV/HPV.
RESULTS: Our results demonstrate successfully meeting WHO targets for HCC and CC in Germany, Italy, and Spain could prevent approximately 9,813 (HCC/CC: 4,746/5,067) cancer cases; resulting in 5,580 (2,357/3,223) fewer patients requiring surgical procedures, 10,583 (8,209/2,374) fewer needing systemic anti-cancer therapy (SACT) treatments (including 1,394 targeted therapies), and 2,425 (104/2,321) fewer patients requiring radiotherapy sessions each year. Furthermore, if a 90% elimination rate were achieved for the other tumors, an additional 18,359 patients would avoid an HPV-related tumor, resulting in 10,812 fewer patients needing surgery, 8,721 from SACT, and 8,277 from radiotherapy.
CONCLUSIONS: Adopting WHO elimination strategies could substantially reduce healthcare resource demands for HBV and HPV-related cancers, highlighting the benefits of broader vaccination efforts beyond CC prevention. Broadening HPV vaccination in our scenario analysis beyond CC demonstrated reduced cases of other tumors and led to substantial healthcare savings. Real-world data supports the feasibility of achieving these targets through comprehensive vaccination programs.
METHODS: We assessed the 2023 incidence and HCRU for cancer treatment for hepatocellular carcinoma (HCC) and each HPV-related cancer. We then evaluated potential effects of achieving WHO cancer elimination strategies for HCC and CC by modeling a 90% reduction in HBV infections and reducing CC incidence to fewer than 4 cases per 100,000 women. Next, we evaluated a hypothetical scenario to estimate a 90% reduction in other HPV-related cancers including head & neck, anal, penile, vulvar, and vaginal. The 2023 epidemiological data was sourced from the CancerMPact® database, and we applied Population Attributable Fractions (PAFs) to estimate cancer cases linked to HBV/HPV.
RESULTS: Our results demonstrate successfully meeting WHO targets for HCC and CC in Germany, Italy, and Spain could prevent approximately 9,813 (HCC/CC: 4,746/5,067) cancer cases; resulting in 5,580 (2,357/3,223) fewer patients requiring surgical procedures, 10,583 (8,209/2,374) fewer needing systemic anti-cancer therapy (SACT) treatments (including 1,394 targeted therapies), and 2,425 (104/2,321) fewer patients requiring radiotherapy sessions each year. Furthermore, if a 90% elimination rate were achieved for the other tumors, an additional 18,359 patients would avoid an HPV-related tumor, resulting in 10,812 fewer patients needing surgery, 8,721 from SACT, and 8,277 from radiotherapy.
CONCLUSIONS: Adopting WHO elimination strategies could substantially reduce healthcare resource demands for HBV and HPV-related cancers, highlighting the benefits of broader vaccination efforts beyond CC prevention. Broadening HPV vaccination in our scenario analysis beyond CC demonstrated reduced cases of other tumors and led to substantial healthcare savings. Real-world data supports the feasibility of achieving these targets through comprehensive vaccination programs.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE716
Topic
Economic Evaluation, Epidemiology & Public Health, Health Policy & Regulatory
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology, Vaccines